Ignite Creation Date:
2024-07-17 @ 10:41 AM
Last Modification Date:
2024-10-26 @ 3:34 PM
Study NCT ID:
NCT06500000
Status:
COMPLETED
Last Update Posted:
2024-07-15
First Post:
2024-06-30
Brief Title:
The Plasma Metabolomics Profiling of Primary Aldosteronism
Sponsor:
Third Military Medical University
Organization:
Third Military Medical University
Study Overview
Official Title:
The Plasma Metabolomics Profiling of Primary Aldosteronism
Status:
COMPLETED
Status Verified Date:
2024-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Primary aldosteronism PA characterized by overt renin-independent aldosterone production is the most common form endocrine hypertension Compared with blood pressure-matched cases of essential hypertension EH PA is associated with a higher risk of cardiovascular morbidity and mortality It is estimated that PA affects at least 10 of hypertensive patients and up to 25 of treatment-resistant hypertension The major subtypes of PA are comprised of bilateral idiopathic hyperaldosteronism IHA and unilateral aldosterone-producing adenoma APA The screening confirmatory testing and subtype differentiation of PA for therapeutic management is a multi-step and complex process resulting in low screening rates and poor clinical recognition
PA is an independent risk factor for metabolic morbidity Metabolomic profiling is a relatively new strategy for the diagnosis and prognosis of disease through identification and quantification of various metabolites In the current study we aimed to investigate the potential biomakers for discriminating PA from EH as well as subtype classification for PA by untargeted metabolomics
PA is an independent risk factor for metabolic morbidity Metabolomic profiling is a relatively new strategy for the diagnosis and prognosis of disease through identification and quantification of various metabolites In the current study we aimed to investigate the potential biomakers for discriminating PA from EH as well as subtype classification for PA by untargeted metabolomics
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None